ZA202007347B - Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents
Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical compositionInfo
- Publication number
- ZA202007347B ZA202007347B ZA2020/07347A ZA202007347A ZA202007347B ZA 202007347 B ZA202007347 B ZA 202007347B ZA 2020/07347 A ZA2020/07347 A ZA 2020/07347A ZA 202007347 A ZA202007347 A ZA 202007347A ZA 202007347 B ZA202007347 B ZA 202007347B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- addition salt
- crystal form
- receptor agonist
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202007347B true ZA202007347B (en) | 2021-10-27 |
Family
ID=68387039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/07347A ZA202007347B (en) | 2018-05-04 | 2020-11-25 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (enExample) |
| EP (2) | EP4353719B1 (enExample) |
| JP (3) | JP7275253B2 (enExample) |
| KR (2) | KR102672632B1 (enExample) |
| AU (1) | AU2018421487B2 (enExample) |
| CA (1) | CA3099196A1 (enExample) |
| ES (1) | ES2978392T3 (enExample) |
| IL (3) | IL278464B2 (enExample) |
| MX (1) | MX2020011665A (enExample) |
| NZ (1) | NZ770323A (enExample) |
| SG (1) | SG11202010969UA (enExample) |
| WO (1) | WO2019210511A1 (enExample) |
| ZA (1) | ZA202007347B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7275253B2 (ja) * | 2018-05-04 | 2023-05-17 | スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
| CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1549640A4 (en) * | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS |
| AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (zh) * | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | 一种免疫调节化合物、其用途和包含其的药物组合物 |
| CN105315266B (zh) | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN115772166B (zh) * | 2017-01-11 | 2025-01-03 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| JP7275253B2 (ja) * | 2018-05-04 | 2023-05-17 | スーチョウ・コネクト・バイオファーマシューティカルズ・リミテッド | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
-
2018
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 IL IL312512A patent/IL312512B2/en unknown
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 NZ NZ770323A patent/NZ770323A/en unknown
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko not_active Ceased
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL324507A (en) | Thr-beta receptor agonist compound and method for its preparation and use | |
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| SG11202011883RA (en) | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof | |
| SG11202104687SA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| SG11202104686QA (en) | Ret inhibitors, pharmaceutical compositions and uses thereof | |
| SI3565550T1 (sl) | Farmacevtske sestave, ki vsebujejo meloksikam in rizatriptan | |
| IL276888A (en) | Pharmaceutical compositions containing timolol | |
| EP3714901A4 (en) | ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| ZA201804387B (en) | Pharmaceutical composition containing 2-{4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide | |
| ZA202006157B (en) | Pharmaceutical composition of kor receptor agonist | |
| PT3632436T (pt) | Composição farmacêutica compreendendo sais de lenvatinib | |
| SG11202010969UA (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| EP3650444B8 (en) | Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof | |
| EP3939998A4 (en) | PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF | |
| EP3760620A4 (en) | PRESCRIBER ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | |
| SG11201605742TA (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| PL3811941T3 (pl) | Kompozycja farmaceutyczna zawierająca ilaprazol i jego sól oraz sposób jej wytwarzania | |
| IL279202A (en) | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use | |
| HK40065027A (en) | THRβ RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOF | |
| PL3868768T3 (pl) | Farmaceutyczny kryształ kontezolidu acefosamilu, sposób jego wytwarzania i jego zastosowania | |
| EP3889157C0 (en) | SALT AND CRYSTALLINE FORM OF A FUROPYRIMIDINE COMPOUND AND THEIR PHARMACEUTICAL USE | |
| HK40048019A (en) | Farnesoid x receptor agonists for the treatment of disease | |
| ZA201804996B (en) | Ophthalmic pharmaceutical composition containing brinzolamide and timolol and method for the preparation thereof | |
| PT3431106T (pt) | Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso | |
| GB201812022D0 (en) | Pharmaceutical methods and compositions |